Targeting PD-1/PD-L1 in lung cancer: current perspectives

References

• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• TopalianSLHodiFSBrahmerJRSafety, activity, and immune correlates of anti-PD-1 antibody in cancerN Engl J Med2012366262443245422658127
   PubMed Web of Science ®Google Scholar
• BrahmerJRDrakeCGWollnerIPhase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlatesJ Clin Oncol201028193167317520516446
   PubMed Web of Science ®Google Scholar
• DunnGPBruceATIkedaHOldLJSchreiberRDCancer immunoediting: from immunosurveillance to tumor escapeNat Immunol200231199199812407406
   PubMed Web of Science ®Google Scholar
• LenschowDJWalunasTLBluestoneJACD28/B7 system of T cell costimulationAnnu Rev Immunol1996142332588717514
   PubMed Web of Science ®Google Scholar
• SchwartzRHCostimulation of T lymphocytes: the role of CD28, CTLA-4, and B7/BB1 in interleukin-2 production and immunotherapyCell1992717106510681335362
   PubMed Web of Science ®Google Scholar
• ChenLAsheSBradyWACostimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4Cell1992717109311021335364
   PubMed Web of Science ®Google Scholar
• TownsendSEAllisonJPTumor rejection after direct costimulation of CD8+ T cells by B7-transfected melanoma cellsScience199325950933683707678351
   PubMed Web of Science ®Google Scholar
• DenkertCLoiblSNoskeATumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancerJ Clin Oncol201028110511319917869
   PubMed Web of Science ®Google Scholar
• LoiSSirtaineNPietteFPrognostic and predictive value of tumor-infiltrating lymphocytes in a phase III randomized adjuvant breast cancer trial in node-positive breast cancer comparing the addition of docetaxel to doxorubicin with doxorubicin-based chemotherapy: BIG 02-98J Clin Oncol201331786086723341518
   PubMed Web of Science ®Google Scholar
• GalonJCostesASanchez-CaboFType, density, and location of immune cells within human colorectal tumors predict clinical outcomeScience200631357951960196417008531
   PubMed Web of Science ®Google Scholar
• FridmanWHPagèsFSautès-FridmanCGalonJThe immune con-texture in human tumours: impact on clinical outcomeNat Rev Cancer201212429830622419253
   PubMed Web of Science ®Google Scholar
• ZhangLConejo-GarciaJRKatsarosDIntratumoral T cells, recurrence, and survival in epithelial ovarian cancerN Engl J Med2003348320321312529460
   PubMed Web of Science ®Google Scholar
• GrosARobbinsPFYaoXPD-1 identifies the patient-specific CD8+ tumor-reactive repertoire infiltrating human tumorsJ Clin Invest201412452246225924667641
   PubMed Web of Science ®Google Scholar
• LinsleyPSBradyWUrnesMGrosmaireLSDamleNKLedbetterJACTLA-4 is a second receptor for the B cell activation antigen B7J Exp Med199117435615691714933
   PubMed Web of Science ®Google Scholar
• SalviSFontanaVBoccardoSEvaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancerCancer immunol Immunother20126191463147222318401
   PubMed Web of Science ®Google Scholar
• ThompsonCBAllisonJPThe emerging role of CTLA-4 as an immune attenuatorImmunity1997744454509354465
   PubMed Web of Science ®Google Scholar
• WalunasTLLenschowDJBakkerCYCTLA-4 can function as a negative regulator of T cell activationImmunity1994154054137882171
   PubMed Web of Science ®Google Scholar
• KearneyERWalunasTLKarrRWAntigen-dependent clonal expansion of a trace population of antigen-specific CD4+ T cells in vivo is dependent on CD28 costimulation and inhibited by CTLA-4J Immunol19951553103210367543510
   PubMed Web of Science ®Google Scholar
• KrummelMFAllisonJPCD28 and CTLA-4 have opposing effects on the response of T cells to stimulationJ Exp Med199518224594657543139
   PubMed Web of Science ®Google Scholar
• KrummelMFSullivanTJAllisonJPSuperantigen responses and co-stimulation: CD28 and CTLA-4 have opposing effects on T cell expansion in vitro and in vivoInt Immunol1996845195238671638
   PubMed Web of Science ®Google Scholar
• TivolEABorrielloFSchweitzerANLynchWPBluestoneJASharpeAHLoss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4Immunity1995355415477584144
   PubMed Web of Science ®Google Scholar
• WaterhousePPenningerJMTimmsELymphoproliferative disorders with early lethality in mice deficient in Ctla-4Science199527052389859887481803
   PubMed Web of Science ®Google Scholar
• ChambersCASullivanTJAllisonJPLymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cellsImmunity1997768858959430233
   PubMed Web of Science ®Google Scholar
• HuangCTWorkmanCJFliesDRole of LAG-3 in regulatory T cellsImmunity200421450351315485628
   PubMed Web of Science ®Google Scholar
• GandhiMKLambleyEDuraiswamyJExpression of LAG-3 by tumor-infiltrating lymphocytes is coincident with the suppression of latent membrane antigen-specific CD8+ T-cell function in Hodgkin lymphoma patientsBlood200610872280228916757686
   PubMed Web of Science ®Google Scholar
• ZhuCAndersonACSchubartAThe TIM-3 ligand galectin-9 negatively regulates T helper type 1 immunityNat Immunol20056121245125216286920
   PubMed Web of Science ®Google Scholar
• SabatosCAChakravartiSChaEInteraction of TIM-3 and TIM-3 ligand regulates T helper type 1 responses and induction of peripheral toleranceNat Immunol20034111102111014556006
   PubMed Web of Science ®Google Scholar
• SakuishiKApetohLSullivanJMBlazarBRKuchrooVKAndersonACTargeting TIM-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunityJ Exp Med2010207102187219420819927
   PubMed Web of Science ®Google Scholar
• GaoXZhuYLiGTIM-3 expression characterizes regulatory T cells in tumor tissues and is associated with lung cancer progressionPLoS One201272e3067622363469
   PubMed Web of Science ®Google Scholar
• ZhuangXZhangXXiaXEctopic expression of TIM-3 in lung cancers: a potential independent prognostic factor for patients with NSCLCAm J Clin Pathol2012137697898522586058
   PubMed Web of Science ®Google Scholar
• ZhouPShafferDRAlvarez AriasDAIn vivo discovery of immunotherapy targets in the tumour microenvironmentNature20145067486525724476824
   PubMed Web of Science ®Google Scholar
• Le MercierIChenWLinesJLVISTA regulates the development of protective antitumor immunityCancer Res20147471933194424691994
   PubMed Web of Science ®Google Scholar
• VelchetiVSchalperKACarvajalDEProgrammed death ligand-1 expression in non-small cell lung cancerLab Invest201494110711624217091
   PubMed Web of Science ®Google Scholar
• ChenYYWangLBZhuHLRelationship between programmed death-ligand 1 and clinicopathological characteristics in non-small cell lung cancer patientsChin Med Sci J201328314715124074616
   PubMedGoogle Scholar
• ChenYBMuCYHuangJAClinical significance of programmed death-1 ligand-1 expression in patients with non-small cell lung cancer: a 5-year-follow-up studyTumori201298675175523389362
   PubMed Web of Science ®Google Scholar
• PardollDMThe blockade of immune checkpoints in cancer immunotherapyNat Rev Cancer201212425226422437870
   PubMed Web of Science ®Google Scholar
• DongHStromeSESalomaoDRTumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasionNat Med20028879380012091876
   PubMed Web of Science ®Google Scholar
• ButteMJKeirMEPhamduyTBSharpeAHFreemanGJProgrammed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responsesImmunity200727111112217629517
   PubMed Web of Science ®Google Scholar
• ChenZFillmoreCMHammermanPSKimCFWongKKNon-small-cell lung cancers: a heterogeneous set of diseasesNat Rev Cancer201414853554625056707
   PubMed Web of Science ®Google Scholar
• KarwaczKBricogneCMacDonaldDPD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cellsEMBO Mol Med201131058159221739608
   PubMed Web of Science ®Google Scholar
• FreireJAjonaDde BiurrunGSilica-induced chronic inflammation promotes lung carcinogenesis in the context of an immunosuppressive microenvironmentNeoplasia201315891392423908592
   PubMed Web of Science ®Google Scholar
• O’CallaghanDSO’DonnellDO’ConnellFO’ByrneKJThe role of inflammation in the pathogenesis of non-small cell lung cancerJ Thorac Oncol20105122024203621155185
   PubMed Web of Science ®Google Scholar
• LiCWXiaWHuoLEpithelial-mesenchymal transition induced by TNF-α requires NF-κB-mediated transcriptional upregulation of Twist1Cancer Res20127251290130022253230
   PubMed Web of Science ®Google Scholar
• SoTTakenoyamaMMizukamiMHaplotype loss of HLA class I antigen as an escape mechanism from immune attack in lung cancerCancer Res200565135945595215994973
   PubMed Web of Science ®Google Scholar
• ShimizuKNakataMHiramiYYukawaTMaedaATanemotoKTumor-infiltrating Foxp3+ regulatory T cells are correlated with cyclooxygenase-2 expression and are associated with recurrence in resected non-small cell lung cancerJ Thorac Oncol20105558559020234320
   PubMed Web of Science ®Google Scholar
• SrivastavaMKAnderssonÅZhuLMyeloid suppressor cells and immune modulation in lung cancerImmunotherapy20124329130422401635
   PubMed Web of Science ®Google Scholar
• BrahmerJHornLAntoniaSSurvival and long-term follow-up of the phase I trial of nivolumab (Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously treated advanced non-small cell lung cancer (NSCLC)Proc Am Soc Clin Oncol2013
   Google Scholar
• GettingerSChowLQBorghaeiHSafety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced non-small cell lung cancer (NSCLC)Int J Radiat Oncol Biol Phys2014905S34S35
   Google Scholar
• RizviNAMazièresJPlanchardDActivity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trialLancet Oncol201516325726525704439
   PubMed Web of Science ®Google Scholar
• AntoniaSJBrahmerJRGettingerSNivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with platinum-based doublet chemotherapy (PT-DC) in advanced non-small cell lung cancer (NSCLC)Int J Radiat Oncol Biol Phys2014905S2
   Web of Science ®Google Scholar
• GaronEBalmanoukianAHamidOPreliminary safety and clinical activity of MK-3475 in previously treated patients (pts) with non-small cell lung cancer (NSCLC)Presented at: Annual Congress of the American Society of Clinical Oncology (ASCO)2014
   Google Scholar
• GaronEBGandhiLRizviNAntitumor activity of pembrolizumab (pembro; MK-3475) and correlation with programmed death ligand 1 (PD-L1) expression in a pooled analysis of patients (pts) with advanced non-small cell lung carcinoma (NSCLC)Ann Oncol201425Supplement 5v1v41
   Google Scholar
• BrahmerJRTykodiSSChowLQSafety and activity of anti-PD-L1 antibody in patients with advanced cancerN Engl J Med2012366262455246522658128
   PubMed Web of Science ®Google Scholar
• KhleifSLutzkyJSegalNMEDI4736, an anti-PD-L1 antibody with modified Fc domain: preclinical evaluation and early clinical results from a phase 1 study in patients with advanced solid tumorsPresented at: European Cancer Congress20132013
   Google Scholar
• LutzkyJAntoniaSJBlake-HaskinsAA phase 1 study of MEDI4736, an anti–PD-L1 antibody, in patients with advanced solid tumorsJ Clin Oncol2014325s Suppl; abstr 3001
   Web of Science ®Google Scholar
• SegalNHAntoniaSBrahmerJPreliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibodyJ Clin Oncol2014325s Suppl; abstr 3002
   PubMed Web of Science ®Google Scholar
• SpigelDGettingerSHornLClinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC)Proc Am Soc Clin Oncol201331
   Web of Science ®Google Scholar
• SoriaJCCruzCBahledaRClinical activity, safety, and biomarkers of a PD-L1 blockade in non-small cell lung cancer (NSCLC9: additional analyses from a clinical study of the engineered antibody MPDL3280A (anti-PDL1)Presented at: European Cancer Congress20132013
   Google Scholar
• GandhiLBalmanoukianAHuiRMK-3475 (anti-PD-1 monoclonal antibody) for non-small cell lung cancer (NSCLC): antitumor activity and association with tumor PD-L1 expressionPresented at: Annual Congress of the American Association for Cancer Research20142014
   Google Scholar
• GettingerSNShepherdFAAntoniaSJFirst-line nivolumab (anti-PD-1; BMS-936558, ONO-4538) monotherapy in advanced NSCLC: safety, efficacy, and correlation of outcomes with PD-L1 statusJ Clin Oncol2014325s Suppl; abstr 8024
   Web of Science ®Google Scholar
• HerbstRSSoriaJCKowanetzMPredictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patientsNature2014515752856356725428504
   PubMed Web of Science ®Google Scholar
• BrahmerJRHornLGandhiLNivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients (pts) with advanced non-small-cell lung cancer (NSCLC): survival and clinical activity by subgroup analysisJ Clin Oncol2014325s Suppl; abstr 8112
   Web of Science ®Google Scholar
• BrahmerJRRizviNALutzkyJClinical activity and biomarkers of MEDI4736, an anti-PD-L1 antibody, in patients with NSCLCJ Clin Oncol2014325s Suppl; abstr 8021
   Web of Science ®Google Scholar
• GaronEBalmanoukianAHamidOPreliminary clinical safety and activity of MK-3475 mono-therapy for the treatment of previously treated patients with non-small cell lung cancerIASLC 15th World Conference on Lung Cancer2013 Abstract MO18.02
   Google Scholar
• TaubeJMKleinABrahmerJRAssociation of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapyClin Cancer Res201420195064507424714771
   PubMed Web of Science ®Google Scholar
• TumehPCHarviewCLYearleyJHPD-1 blockade induces responses by inhibiting adaptive immune resistanceNature2014515752856857125428505
   PubMed Web of Science ®Google Scholar
• SnyderAMakarovVMerghoubTGenetic basis for clinical response to CTLA-4 blockade in melanomaN Engl J Med2014371232189219925409260
   PubMed Web of Science ®Google Scholar
• HechtSSTobacco smoke carcinogens and lung cancerJ Natl Cancer Inst199991141194121010413421
   PubMedGoogle Scholar
• HellmannMDCreelanBCWooKSmoking history and response to nivolumab in patients with advanced NSCLCsAnn Oncol201425Supplement 4iv426iv470
   Google Scholar
• LynchTJBondarenkoILuftAIpilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II studyJ Clin Oncol201230172046205422547592
   PubMed Web of Science ®Google Scholar
• XuCFillmoreCMKoyamaSLoss of Lkb1 and Pten leads to lung squamous cell carcinoma with elevated PD-L1 expressionCancer Cell201425559060424794706
   PubMed Web of Science ®Google Scholar
• VelchetiVRimmDLSchalperKASarcomatoid lung carcinomas show high levels of programmed death ligand-1 (PD-L1)J Thorac Oncol20138680380523676558
   PubMed Web of Science ®Google Scholar
• ReckMBondarenkoILuftAIpilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trialAnn Oncol2013241758322858559
   PubMed Web of Science ®Google Scholar
• TaubeJMAndersRAYoungGDColocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escapeSci Transl Med20124127127ra37
   PubMed Web of Science ®Google Scholar
• SprangerSSpaapenRMZhaYUp-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cellsSci Transl Med20135200200ra116
   PubMed Web of Science ®Google Scholar
• AkbayEAKoyamaSCarreteroJActivation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumorsCancer Discov20133121355136324078774
   PubMed Web of Science ®Google Scholar
• PeggsKSQuezadaSAChambersCAKormanAJAllisonJPBlockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodiesJ Exp Med200920681717172519581407
   PubMed Web of Science ®Google Scholar
• WinogradRByrneKTEvansRAInduction of T-cell immunity overcomes complete resistance to PD-1 and CTLA-4 blockade and improves survival in pancreatic carcinomaCancer Immunol Res20153439941125678581
   PubMed Web of Science ®Google Scholar
• BulliardYJolicoeurRZhangJDranoffGWilsonNSBrogdonJLOX40 engagement depletes intratumoral Tregs via activating FcγRs, leading to antitumor efficacyImmunol Cell Biol201492647548024732076
   PubMed Web of Science ®Google Scholar
• Feder-MengusCWylerSHudolinTHigh expression of indoleamine 2,3-dioxygenase gene in prostate cancerEur J Cancer200844152266227518619832
   PubMed Web of Science ®Google Scholar
• FeigCJonesJOKramanMTargeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti-PD-L1 immunotherapy in pancreatic cancerProc Natl Acad Sci U S A201311050202122021724277834
   PubMed Web of Science ®Google Scholar
• ZhuYKnolhoffBLMeyerMACSF1/CSF1R blockade repro-grams tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer modelsCancer Res201474185057506925082815
   PubMed Web of Science ®Google Scholar
• HasmimMNomanMZMessaiYCutting edge: hypoxia-induced Nanog favors the intratumoral infiltration of regulatory T cells and macrophages via direct regulation of TGF-β1J Immunol2013191125802580624227785
   PubMed Web of Science ®Google Scholar
• SchadendorfDHodiFSRobertCPooled analysis of long-term survival data from Phase II and Phase III trials of ipilimumab in unresectable or metastatic melanomaJ Clin Oncol Epub292015
   PubMed Web of Science ®Google Scholar
• WooSRTurnisMEGoldbergMVImmune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escapeCancer Res201272491792722186141
   PubMed Web of Science ®Google Scholar
• FourcadeJSunZBenallaouaMUpregulation of TIM-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patientsJ Exp Med2010207102175218620819923
   PubMed Web of Science ®Google Scholar
• NirschlCJDrakeCGMolecular pathways: coexpression of immune checkpoint molecules: signaling pathways and implications for cancer immunotherapyClin Cancer Res201319184917492423868869
   PubMed Web of Science ®Google Scholar
• FourcadeJSunZPaglianoOPD-1 and TIM-3 regulate the expansion of tumor antigen-specific CD8+ T cells induced by melanoma vaccinesCancer Res20147441045105524343228
   PubMed Web of Science ®Google Scholar
• ZhouQMungerMEVeenstraRGCoexpression of TIM-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemiaBlood2011117174501451021385853
   PubMed Web of Science ®Google Scholar
• NgiowSFvon ScheidtBAkibaHYagitaHTengMWSmythMJAnti-TIM-3 antibody promotes T cell IFN-γ-mediated antitumor immunity and suppresses established tumorsCancer Res201171103540355121430066
   PubMed Web of Science ®Google Scholar
• MittalDYoungAStannardKAntimetastatic effects of blocking PD-1 and the adenosine A2A receptorCancer Res201474143652365824986517
   PubMed Web of Science ®Google Scholar
• IannoneRMieleLMaiolinoPPintoAMorelloSAdenosine limits the therapeutic effectiveness of anti-CTLA4 mAb in a mouse melanoma modelAm J Cancer Res20144217218124660106
   PubMed Web of Science ®Google Scholar
• WolchokJDKlugerHCallahanMKNivolumab plus ipilimumab in advanced melanomaN Engl J Med2013369212213323724867
   PubMed Web of Science ®Google Scholar
• AntoniaSGettingerSChowLQNivolumab and ipilimumab in first-line NSCLC: interim phase 1 resultsPresented at: Annual Congress of the American Society of Clinical Oncology (ASCO)2014
   Google Scholar
• FrederickDTPirisACogdillAPBRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanomaClin Cancer Res20131951225123123307859
   PubMed Web of Science ®Google Scholar
• JiangXZhouJGiobbie-HurderAWargoJHodiFSThe activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibitionClin Cancer Res201319359860923095323
   PubMed Web of Science ®Google Scholar
• AtefiMAvramisELassenAEffects of MAPK and PI3K pathways on PD-L1 expression in melanomaClin Cancer Res201420133446345724812408
   PubMed Web of Science ®Google Scholar
• D’InceccoAAndreozziMLudoviniVPD-L1 and PD-1 expression in molecularly selected non-small-cell lung cancer (NSCLC) patientsJ Thorac Oncol20149Supplement 9S7S52
   Google Scholar
• Ait-TaharKBarnardoMCPulfordKCD4 T-helper responses to the anaplastic lymphoma kinase (ALK) protein in patients with ALK-positive anaplastic large-cell lymphomaCancer Res20076751898190117332315
   PubMed Web of Science ®Google Scholar
• GalluzziLSenovillaLZitvogelLKroemerGThe secret ally: immunostimulation by anticancer drugsNat Rev Drug Discov201211321523322301798
   PubMed Web of Science ®Google Scholar
• VisvaderJELindemanGJCancer stem cells: current status and evolving complexitiesCell Stem Cell201210671772822704512
   PubMed Web of Science ®Google Scholar
• ZhengYde la CruzCCSaylesLCA rare population of CD24(+) ITGB4(+)Notch(hi) cells drives tumor propagation in NSCLC and requires Notch3 for self-renewalCancer Cell2013241597423845442
   PubMed Web of Science ®Google Scholar
• RizviNChowLQBorghaeiHSafety and response with nivolumab (anti-PD-1; BMS-936558, ONO-4538) plus erlotinib in patients (pts) with epidermal growth factor receptor mutant (EGFR MT) advanced NSCLCJ Clin Oncol2014325s Suppl; abstr 8022
   PubMed Web of Science ®Google Scholar
• LouYDiaoLByersLAAssociation of epithelial-mesenchymal transition status with PD1/PDL1 expression and a distinct immunophenotype in non-small cell lung cancer: implications for immunotherapy biomarkersJ Clin Oncol2014325s Suppl; abstr 3018
   Web of Science ®Google Scholar
• MathieuJZhangZZhouWHIF induces human embryonic stem cell markers in cancer cellsCancer Res201171134640465221712410
   PubMed Web of Science ®Google Scholar
• HasmimMNomanMZLauriolJHypoxia-dependent inhibition of tumor cell susceptibility to CTL-mediated lysis involves NANOG induction in target cellsJ Immunol201118784031403921911602
   PubMed Web of Science ®Google Scholar
• RoselliMFernandoRIGuadagniFBrachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancerClin Cancer Res201218143868387922611028
   PubMed Web of Science ®Google Scholar
• HuYMintzAShahSRQuinones-HinojosaAHsuWThe FGFR/MEK/ERK/brachyury pathway is critical for chordoma cell growth and survivalCarcinogenesis20143571491149924445144
   PubMed Web of Science ®Google Scholar
• YuanZSyrkinGAdemABlockade of inhibitors of apoptosis (IAPs) in combination with tumor-targeted delivery of tumor necrosis factor-α leads to synergistic antitumor activityCancer Gene Ther2013201465623154431
   PubMed Web of Science ®Google Scholar
• KnightsAJFucikovaJPasamAKoernigSCebonJInhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapyCancer Immunol Immunother201362232133522923192
   PubMed Web of Science ®Google Scholar
• GettingerSNHornLGandhiLLong-term survival, clinical activity, and safety of nivolumab (anti-PD-1; BMS-936558, ONO-4538) in patients (pts) with advanced non-small cell lung cancer (NSCLC)Int J Radiat Oncol Biol Phys2014905S34
   Google Scholar
• RamalingamSSMazièresJPlanchardDPhase II study of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced, refractory squamous non-small cell lung cancerInt J Radiat Oncol Biol Phys201490512661267
   Web of Science ®Google Scholar
• RizviNAShepherdFAAntoniaSJFirst-Line monotherapy with nivolumab (anti-PD-1; BMS-936558, ONO-4538) in advanced non-small cell lung cancer (NSCLC): safety, efficacy, and correlation of outcomes with PD-L1 statusInt J Radiat Oncol Biol Phys2014905S31
   Web of Science ®Google Scholar
• RizviNAGaronEBPatnaikASafety and clinical activity of MK-3475 as initial therapy in patients with advanced non-small cell lung cancer (NSCLC)J Clin Oncol2014325s Suppl; abstr 8007
   PubMed Web of Science ®Google Scholar
• BrahmerJBalmanoukianAGoldbergSDevelopment of MEDI4736, an anti-programmed cell death ligand 1 (PD-L1) antibody, as monotherapy or in combination with other therapies in the treatment of non-small cell lung cancer (NSCLC)J Immunother Cancer20142Suppl 3179
   Google Scholar
• ZatloukalPHeoDSParkKRandomized phase II clinical trial comparing tremelimumab (CP-675,206) with best supportive care (BSC) following first-line platinum-based therapy in patients (pts) with advanced non-small cell lung cancer (NSCLC)J Clin Oncol20092715s Suppl; abstr 8071
   Web of Science ®Google Scholar
• DaudAHamidORibasAAntitumor activity of the anti-PD-1 monoclonal antibody MK-3475 in melanoma: correlation of tumor PD-L1 expression with outcomePresented at: AACR Annual Meeting2014
   Google Scholar
• KeffordRRibasAHamidOClinical efficacy and correlation with tumor PD-L1 expression in patients (pts) with melanoma (MEL) treated with the anti-PD-1 monoclonal antibody MK-3475J Clin Oncol2014325s Suppl; abstr 3005
   Web of Science ®Google Scholar
• SeiwertTYBurtnessBWeissJA phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV–associated head and neck (H/N) cancerJ Clin Oncol2014325s Suppl; abstr 6011
   Web of Science ®Google Scholar
• WeberJSKudchadkarRRYuBSafety, efficacy, and biomark-ers of nivolumab with vaccine in ipilimumab-refractory or -naive melanomaJ Clin Oncol201331344311431824145345
   PubMed Web of Science ®Google Scholar
• MotzerRJRiniBIMcDermottDFNivolumab for metastatic renal cell carcinoma: results of a randomized Phase II trialJ Clin Oncol201533131430143725452452
   PubMed Web of Science ®Google Scholar
• GrossoJHorakCEInzunzaDAssociation of tumor PD-L1 expression and immune biomarkers with clinical activity in patients (pts) with advanced solid tumors treated with nivolumab (anti-PD-1; BMS-936558; ONO-4538)J Clin Oncol201331Suppl abstr 3016
   Google Scholar
• HodiFSSznolMKlugerHMLong-term survival of ipilimumab-naive patients (pts) with advanced melanoma (MEL) treated with nivolumab (anti-PD-1, BMS-936558, ONO-4538) in a phase I trialJ Clin Oncol2014325s Suppl; abstr 9002
   Web of Science ®Google Scholar
• RobertCLongGVBradyBNivolumab in previously untreated melanoma without BRAF mutationN Engl J Med2015372432033025399552
   PubMed Web of Science ®Google Scholar
• PowlesTEderJPFineGDMPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerNature2014515752855856225428503
   PubMed Web of Science ®Google Scholar
• HamidOSosmanJALawrenceDPClinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic melanoma (mM)J Clin Oncol201331Suppl abstr 9010
   PubMed Web of Science ®Google Scholar